

RWANDA

Support for Measles Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme

| 1. | Country: | Rwanda | | | | | | |
|-----|-------------------------------|--|---|--------------|--------------|-------------|---------|--------------------|
| 2. | Vaccine gran | t number: | 13-RWA-08a-Y, 1517-RWA-09a-X, 18-RWA-09a-X, 19-RWA-09a-X, 20-RWA-09a-X | | | | | |
| 3. | Date of Decis | sion Letter: | 30 September 2019 | | | | | |
| 4. | Date of the P | artnership F | ramework A | Agreement: | | 7 June 201 | 3 | |
| 5. | Programme t | itle: | New Vaccin | e Support (N | IVS), Measle | es Rubella, | SD Rout | ine - Strat 1 |
| 6. | Vaccine type: Measles Rubella | | | | | | | |
| 7. | Requested p | roduct prese | entation and formulation of vaccine: | | | | | |
| | Measles Rube | ella, 10 doses | es per vial, LYOPHILISED | | | | | |
| 8. | Programme Duration: 2015-2020 | | | | | | | |
| 9. | Programme I | ogramme Budget (indicative):2 (subject to the terms of the Partnership Framework | | | | | | |
| | Agreement, if applicable) | | | | | | | |
| | | 2015-2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Total ² |
| | Programme Budget (US\$) | 674,942 | 82,000 | - | - | - | - | 756,942 |
| 10. | Vaccine intro | duction gra | nt | | | | | |

| Approval | | | | |
|----------|--------------|---------------|--|--|
| Year | Grant Number | Amount (US\$) | | |
| 2013 | 13-RWA-08a-Y | 299,500 | | |

11. Product switch grant

Not applicable

12. Indicative Annual Amounts:3

(subject to the terms of the Partnership Framework Agreement, if applicable)

| Type of supplies to be purchased with Gavi funds | 2015-2019 | 2020 | 2021 |
|--|-----------|---------|------|
| Number of vaccine doses | | 275,500 | - |
| Annual Amounts (US\$) | 674,942 | 82,000 | - |

UNICEF. The Country shall release its co-financing payments 13. Procurement agency: each year to UNICEF.

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.



14. Self-procurement: Not applicable

15. Co-financing obligations:

Not applicable

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

| | Due dates |
|--|------------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information each year: | |
| Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any | 31 March 2020 |
| proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received | 15 May 2020 |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Gavi Secretariat |

18. Financial clarifications: Not applicable

19. Other conditions:

Country has presented an official request to Gavi to switch from measles vaccine to measlesrubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

| | 2020 |
|--|---------|
| Number of doses of vaccines for Measles Second Dose approved by Gavi | 275,500 |
| Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support. | 120,531 |
| Number of doses of Measles-Rubella vaccine to be funded by country | 154,969 |
| Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance) (US\$) | 101,660 |

Signed by

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019

